Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Friday.

Several other research firms also recently weighed in on KERX. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. Maxim Group set a $9.00 price objective on shares of Keryx Biopharmaceuticals and gave the company a “buy” rating in a research note on Thursday, July 27th. BidaskClub raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Cowen and Company reaffirmed a “market perform” rating on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $7.00 price objective (up from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $7.35.

Keryx Biopharmaceuticals (NASDAQ KERX) traded down $0.08 during trading on Friday, reaching $4.83. 3,248,500 shares of the company’s stock traded hands, compared to its average volume of 2,675,893. The company has a quick ratio of 5.16, a current ratio of 4.46 and a debt-to-equity ratio of 13.95. Keryx Biopharmaceuticals has a 1-year low of $4.47 and a 1-year high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $15.00 million during the quarter, compared to the consensus estimate of $18.88 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The business’s revenue for the quarter was up 138.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.39) earnings per share. equities analysts anticipate that Keryx Biopharmaceuticals will post -1.34 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/11/13/keryx-biopharmaceuticals-inc-kerx-rating-lowered-to-strong-sell-at-valuengine.html.

Several large investors have recently modified their holdings of the company. Fox Run Management L.L.C. purchased a new position in shares of Keryx Biopharmaceuticals during the third quarter valued at about $101,000. Principal Financial Group Inc. increased its position in shares of Keryx Biopharmaceuticals by 4.2% during the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 590 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in shares of Keryx Biopharmaceuticals by 51.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 5,628 shares during the period. Legal & General Group Plc increased its position in shares of Keryx Biopharmaceuticals by 1.2% during the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Keryx Biopharmaceuticals during the second quarter valued at about $183,000. 65.10% of the stock is owned by hedge funds and other institutional investors.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.